Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma. (18th April 2012)

• Record Type: Journal Article
• Authors: Petrich, Adam M.; Sparano, Joseph A.; Parekh, Samir
• Other Names: Leitch Heather Academic Editor.
• Is Part Of: Advances in hematology. Volume 2012(2012)
• Publication Date: 2012-04-18
• Subjects: Hematology -- Periodicals; Hematologic Diseases; Hematology; Hematology; Periodicals; Periodicals; 616.15
• DOI: 10.1155/2012/403648
• Languages: English
• ISSNs: 1687-9104

Abstract

Abstract : Burkitt lymphoma (BL) is a very aggressive subtype of non-Hodgkin's lymphoma that occurs with higher frequency in patients with HIV/AIDS. Patients with HIV-related BL (HIV-BL) are usually treated with high-intensity, multi-agent chemotherapy regimens. The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting. The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-BL, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation.